June 25, 2019
The Spring 2019 issue of the Partners Biobank newsletter for Biobank participants has been released.
May 22, 2018
The Spring 2018 issue of the Partners Biobank newsletter for Biobank participants has been released
September 22, 2017
This summer, I got an email with the subject line, “Help researchers at Mass. General or the Brigham make discoveries.” Think the Boston hospitals — Massachusetts General Hospital and Brigham and Women's Hospital — were hitting me up for a check? Wrong. Not long afterward, as I was passing through a busy lobby of Mass. General, an eye-grabbing kiosk invited me to “Join us to help shape the future of healthcare.” Once again, it sure sounded like a charity appeal. But the recruiters didn't want my money. They wanted my DNA and my medical records, to help them build a massive database for research called a biobank.
July 12, 2017
The Partners Biobank has started returning research results to Biobank participants. These results are genetic variants, also called mutations, that indicate a high risk of developing certain conditions and diseases. The purpose of returning research results is to provide Biobank participants with information that could positively impact their clinical care. Results being returned are genetic variants that the American College of Medical Genetics (ACMG) defines as being actionable. This means that there are screening tests and/or preventative measures for people who have these variants.
June 20, 2017
The Spring/Summer 2017 issue of the Partners Biobank newsletter for Biobank participants has been released.
June 19, 2017
The accurate detection of tissue damage holds the potential to transform medicine through earlier detection of disease, assessment of disease progression, and real time evaluation of treatment. Dr. Mostoslavsky of the Cancer Center at Massachusetts General Hospital and his lab are researching the connection between tissue damage and disease progression through the study of DNA. This new method has the potential to be applied to earlier detection of multiple types of cancer, type 1 diabetes, as well as the evaluation of tissue damage following a traumatic brain injury or stroke.
November 21, 2016
The Fall 2016 issue of the Partners Biobank newsletter for Biobank participants has been released.
September 6, 2016
Drs. I-Cheng Ho and Hui-Hsin Chang of Brigham and Women’s Hospital recently published a paper in Arthritis & Rheumatology on the results of a study they completed using samples from the Partners Biobank. This study investigated the relationship between a variation in a gene and the risk for the development of rheumatoid arthritis (RA). Drs. Ho and Chang found that the variation in this gene leads to increased activity of immune cells, which can cause the inflammation characteristic of RA.
March 22, 2016
Dr. Kathiresan (pictured) and his team of investigators, led by Pradeep Natarajan, MD, and research coordinator Erina Kii in the Center for Human Genetic Research at Massachusetts General Hospital, are looking for a needle in a haystack.
Sekar Kathiresan, MD, uses the Partners Biobank to conduct research that would otherwise be impossible using traditional research methods.
September 3, 2015
We are happy to bring you the newest issue of our Partners Biobank newsletter created for participants in the Biobank project. The Biobank is a collection of samples and data from patients at Brigham and Women’s Hospital and Massachusetts General Hospital that are used for research. It’s been a busy and exciting year for the project.
August 14, 2015
The next large project for the Biobank is to genotype 10,000 DNA samples by the end of 2015 and a total of 25,000-50,000 samples over the next 2-3 years. Genotyping is the process of detecting which variants of genes a person has. These data, generated by analyzing the stored DNA of participants in the Biobank, will provide researchers with valuable information to further understand the influence of genes on health. The project will lead to a greater understanding of the pathways of human disease, and allow us to develop better diagnostics and targeted therapeutics for future generations.